Fulgent Genetics Inc

FLGT remains in a Stage 2 advancing phase with a bullish medium-term bias supported by the active Lockout Rally continuation pattern. Price is currently in a corrective pullback into the 9/21 EMA zone above the rising 50-day MA, offering a disciplined entry point. No short-term exhaustion or overbought stress is visible in the neutral OB/OS context. The speculative strategy demands high selectivity, justifying a Buy Now on shallow pullback acceptance in the EMA zone.

• ↑Acquisitions of Bako and StrataDX drove Q2 revenue to $85.4M, +20% QoQ
• ↑2026 revenue guidance of $330–340M signals 2.3%–5.4% YoY growth
• ↓Largest customer in-house testing cuts 2025 revenue by $59M (83% loss)